Identification of Novel Therapeutic Targets for MAFLD Based on Bioinformatics Analysis Combined with Mendelian Randomization
International Journal of Molecular Sciences · 29.03.2025 · 26 (7) · 3166
DOI: 10.3390/ijms26073166 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 29.03.2025. Verfasst von Jialin Ren und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou 225100, China. Hauptthemen laut MEDLINE: Computational Biology, Mendelian Randomization Analysis, CCAAT-Enhancer-Binding Proteins, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Metabolic-associated fatty liver disease (MAFLD) is a chronic liver condition with limited therapeutic options. To identify novel drug targets, we integrated bioinformatics, Mendelian randomization (MR), and colocalization analyses. Using the Gene Expression Omnibus (GEO) database, we identified differentially expressed genes and constructed protein–protein interaction (PPI) networks, pinpointing 10 hub genes. MR and colocalization analyses revealed that Ubiquitin-like with PHD and ring finger domains 1 (UHRF1) is causally associated with MAFLD and driven by the same causal variant locus, suggesting its potential as a therapeutic target. Molecular docking identified disogenin as a candidate small-molecule drug targeting UHRF1. Drug affinity responsive target stability (DARTS) assays confirmed direct binding between UHRF1 and disogenin. In vitro, disogenin significantly reduced UHRF1 mRNA and protein levels induced by free fatty acids (FFA) in AML12 and HepG2 cells, accompanied by decreased cellular total cholesterol (TC) and triglyceride (TG) levels. In vivo, disogenin administration alleviated hepatic lipid accumulation, inflammation, and fibrosis in methionine/choline-deficient (MCD)-diet-fed mice. This study identifies UHRF1 as a promising therapeutic target for MAFLD and validates disogenin as a potential therapeutic agent, providing a foundation for further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou 225100, China.
- Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Senile Diseases, Yangzhou University, Yangzhou 225100, China.
Zitieren
APA
Ren, J., & Wu, M. (2025). Identification of Novel Therapeutic Targets for MAFLD Based on Bioinformatics Analysis Combined with Mendelian Randomization. International Journal of Molecular Sciences, 26(7), 3166. https://doi.org/10.3390/ijms26073166
Vancouver
Ren J, Wu M. Identification of Novel Therapeutic Targets for MAFLD Based on Bioinformatics Analysis Combined with Mendelian Randomization. International Journal of Molecular Sciences. 2025;26(7):3166. doi:10.3390/ijms26073166
BibTeX
@article{Ren2025,
author = {Ren, Jialin and Wu, Min},
title = {Identification of Novel Therapeutic Targets for MAFLD Based on Bioinformatics Analysis Combined with Mendelian Randomization},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {7},
pages = {3166},
doi = {10.3390/ijms26073166}
}
EUVIMED